Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
6.25
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
6.26
+0.01 (0.16%)
After-hours: Dec 5, 2025, 4:00 PM EST
Kezar Life Sciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
45.77M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KZR News
- 24 days ago - Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 - Business Wire
- 7 weeks ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives - Business Wire
- 3 months ago - Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 4 months ago - Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 months ago - Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire
- 6 months ago - Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Business Wire
- 7 months ago - Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire